News from the South African Association for Clinical Biochemistry
Total Page:16
File Type:pdf, Size:1020Kb
VISIT WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760 Vol. 28 No.6 • 10/2011 DAILY CLINICAL LAB NEWS Tumor Profiling Assay to Clinical and Virological Factors Gene Test Predicts Improve Cancer Care Influence Dengue Immunoassay Cancer in Pancreatic Cysts tumor-profiling assay will be n evaluation has been made early detection of dengue virus gene-based test has been AAbased on targeted panel AAof the factors that influence infection. AAdeveloped that distinguishes enrichment and next generation the performance of an antigen A team from the Institute precancerous pancreatic cysts sequencing (NGS). It will improve capture assay and other markers Pasteur in Phnom Penh (Cam- from benign vesicles by parallel cancer care by providing specific of dengue disease severity. bodia; www.pasteur-kh.org) col- sequencing. information about individual Dengue nonstructural protein lected blood from patients hospi- Genetic analysis of precancer- patients, thereby facilitating per- 1 (NS1) may be used in simple talized during the 2006 and 2007 ous fluid filled cysts and the search sonalized treatment strategies. antigen-capture enzyme-linked dengue epidemics in Cambodia. for mutations may eventually help The assay will detect mutations immunosorbent assay (ELISA) for Blood samples were tested for more than a million patients each Cont’d on page 8 Cont’d on page 4 Cont’d on page 6 Sensitive Blood Test Multiplex Assay Detects Prion Diseases Detects Drugs novel assay has been devel- Detects Drugs AAoped that will rapidly screen blood plasma for variant in Oral Fluid Creutzfeldt-Jacob disease (vCJD). An integrated antibody-based solid-state device onto approach with an improved real- Awhich antibodies spe- time quaking-induced protein cific to different drug com- conversion (RT-QuIC) reaction pounds are immobilized enhanced the detection of vCJD and stabilized, allows the Cont’d on page 4 simultaneous detection of multiple drug classes and INSIDE drug metabolites from a single undivided specimen. Clinical News . 2-26 See article on page 12 IFCC News . 27 Image: Courtesy of Randox Laboratories EFCC Corner . 30 VISIT ® Digital Pathology Application LINKXPRESS COM Released for iPad and iPhone Product News . 16-22 READER SERVICE PORTAL digital pathology viewing application with Renew/Start your Technical Literature . 26 Abuilt-in educational content from insti- Free Subscription tutes and pathologists was released for iPad Industry News . 33 Access Interactive and iPhone. Digital Magazine Users can try Digital Pathology for free International Calendar . 34 and view, zoom and navigate digital slides Instant Online through the high performance viewer. PUBLISHED IN COOPERATION WITH Product Information: Cont’d on page 8 ® International Federation Identify LinkXpress codes of Genetic Test Diagnoses Breath Test for Immune of Clinical Chemistry 1 and Laboratory Medicine interest as you read magazine Lipid Metabolism Disorder Response to H1N1 Virus Click on LinkXpress.com GLOBETECH 2 to reach reader service portal genetic diagnostic platform can novel breath test detects peo- >>>MEDIA <<< be used to identify patients ple who have an immune Mark code(s) of interest on AA AA with inherited disorder of lipopro- response to the Influenza A virus 3 ® Scan with LinkXpress inquiry matrix tein metabolism characterized by strain H1N1. The test would help elevated levels of total and low-den- to ease future vaccine shortages by Smartphone If your subscription sity lipoprotein (LDL) cholesterol. identifying the people who have to Access is not renewed every 12 months The platform includes the use of already been infected with the flu your Free Subscription may be Latest News automatically discontinued a DNA micro array, the detection of virus. Cont’d on page 8 Cont’d on page 2 LabMedica for daily laboratory medicine news click to www.labmedica.com Breath Test for Immune Response to H1N1 Virus In a study, published July 15, 2011, in H1N1 vaccine via a nasal spray and the IOP Publishing’s Journal of Breath breath test was administered on each of the Research, scientists investigated the easy, following seven days. noninvasive breath test to measure biomol- Samples of exhaled NO were provided ecules that accumulate in response to the by six participants prior to vaccination. H1N1 strain of the flu virus. Nitric oxide is a test approved by the US Investigators from Cleveland Clinic Food and Drug Administration (FDA; (Ohio, USA; http://my.clevelandclinic.org) Silver Spring, MD, USA; www.fda.gov) for and Syft Technologies (Christchurch, New monitoring inflammation and asthma. Zealand; www.syft.com) included 11 indi- Production of exhaled nitric oxide (NO) viduals in their study. Nine of these partic- has also been linked to influenza and viral ipants were given the live attenuated infection. The breath test examined exhaled nitric oxide (NO) – a biomolecule whose production has previously been linked to influenza and viral infection and has been speculated to play a ben- eficial role in viral clearance. The results showed a peak in NO levels in all subjects on the third day after vaccination. There were no signif- icant differences in NO levels on any other day. Of the 11 other compounds exam- ined in the study, only one compound – isoprene – showed an elevated level, also on day three. Increased levels of isoprene, a compound produced within the body and a major constituent of exhaled breath, have been reported to reflect oxidative stress in airways. Previous findings show that the highest number, and severity, of symp- toms related to a H1N1 infection occur on day three, suggesting, along with this study, that this is when an immune response is triggered in the body. A breath test, measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus. Study coauthor Dr. Raed Dweik, professor of medicine and director of the pulmonary vascular program at the Cleveland Clinic, said when the H1N1 epidemic occurred in 2009 physicians were faced with a dilemma related to patient treatment. “We all have nitric oxide in our breath because our lungs make it, but with different levels,” said Prof. Dweik. “If you have an infection or an inflam- mation or if you have asthma, it goes up.” Prof. Dweik cautions that while the work is “rather preliminary,” he sees it as proof of the concept that breath can be used to monitor the vaccination and, it is hoped, the infection. Image: Colored scanning electron micro- graph (SEM) of H1N1 flu virus particles (virions, orange) on a cell (Photo cour- tesy of the NIBSC). LabMedica International October/2011 2 LINKXPRESS COM LMI-10-11 101 VISIT US AT Stand: Curie E65 / D68 LINKXPRESS COM LMI-10-11 102 LabMedica Clinical and Virological Factors labmedica.com EDITORIAL BOARD Influence Dengue Immunoassay Rosa I. Sierra-Amor Mexico Robby Bacchus United Kingdom cont’d from cover Edward J. Bottone United States Claus Christiansen Denmark hematocrit and platelet count as well as for other bio- Bernard Gouget France logical parameters necessary for patients’ follow-up. Anders Kallner Sweden Sera were tested for dengue using serology and Tadashi Kawai Japan John A. Koepke United States molecular methods at the Institute Pasteur in John B. Lines United Kingdom Cambodia. Dengue infection was confirmed in 243 Donald Moss United Kingdom Andreas Rothstein Colombia of 339 symptomatic patients and in 17 asymptomatic Dmitry B. Saprygin Russia individuals out of 214 household members tested. Gérard Siest France Overall sensitivity and specificity of Platelia NS1 Andrew Wootton Australia Ag kit were 57.5% and 100% respectively. When the A GLOBETECH PUBLICATION NS1 Ag assay was combined with immunoglobulin Published in cooperation with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and IgM antibody capture ELISA, the sensitivity was sig- European Federation of Clinical Chemistry and Laboratory nificantly increased for dengue diagnosis. NS1 Ag Medicine (EFCC). positivity rate was found significantly higher in Publishers of: HospiMedica International • HospiMedica en Español HospiMedica China • Medical Imaging International • LabMedica International dengue fever (DF) cases than in fatal dengue hemor- LabMedica en Español • LabMedica China • Bio Research International ly across the various forms of dengue infection or dis- HospiMedica.com • LabMedica.com • Medimaging.net • BiotechDaily.com rhagic fever (DHF) and dengue shock syndrome ease. Sensitivity was highest in patients sampled dur- Dan Gueron Publisher (DSS). It was higher in primary rather than in second- ing the first three days after onset of fever, in patients Jill Roberge Editorial Director ary infections, in patients with a high viremia (>5 Jacqueline Miller, PhD News Director with primary infection, DENV-1 infection, with high Raymond L Jacobson, PhD News Editor log/mL), and in patients infected with the dengue Jerry Slutzky, PhD News Editor level of viremia and in DF rather than DHF/DSS. The viral strain DENV-1. In asymptomatic individuals, the Andreas Rothstein News Editor semi-quantitative approach of the test, demonstrated Marcela Jensen Assistant Editor NS1 Ag capture sensitivity tends to be lower than Joseph Ciprut Assistant Editor that the NS1 antigen level was significantly correlat- that in symptomatic patients. Milder disease severity Brenda Silva New Products Editor ed to the level of viremia and that the low level of Paul Mills Regional Director was